Allogene Therapeutics Publishes Preclinical Data in Clinical Cancer Research Supporting DLL3 as a Potential AlloCAR T™ Target for Small Cell Lung Cancer
January 25 2023 - 7:30AM
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage
biotechnology company pioneering the development of allogeneic CAR
T (AlloCAR T™) products for cancer, today announced the publication
of a preclinical study demonstrating delta-like ligand 3 (DLL3) is
a promising tumor target for AlloCAR T™ in small cell lung
cancer (SCLC). The findings were published in Clinical Cancer
Research, a journal of the American Association for Cancer Research
(AACR).
SCLC is an aggressive disease with limited treatment options.
Approximately 30,000 patients in the United States are affected
each year with this disease which has a 5-year overall survival
rate of approximately 7%.1 DLL3, with high expression on tumors and
limited expression in normal tissue, is a promising target for SCLC
and potentially other solid tumors.
“As a leader in allogeneic CAR T research and development, we
are committed to exploring the potential of this therapeutic
modality across a broad range of indications, including in solid
tumors where there is significant need," said Barbra Sasu, Ph.D.,
Chief Scientific Officer at Allogene.
This study describes the selection of ALLO-213 as an allogeneic
CAR T development candidate targeting DLL3 from a large number of
single chain variable fragment (scFv)-based anti-DLL3 CAR
candidates. The selection of ALLO-213 was based on potency and
specificity against SCLC cell lines in vitro and in vivo, including
cell lines with very low antigen density to establish sensitivity.
The results from the pre-clinical study showed:
- No DLL3 on target toxicity was observed in preclinical models
supporting a potentially attractive safety profile
- Clinical DLL3 CAR candidates controlled DLL3+ tumor growth in
mice without normal tissue toxicity
About Allogene TherapeuticsAllogene
Therapeutics, with headquarters in South San Francisco, is a
clinical-stage biotechnology company pioneering the development of
allogeneic chimeric antigen receptor T cell (AlloCAR T™) products
for cancer. Led by a management team with significant experience in
cell therapy, Allogene is developing a pipeline of “off-the-shelf”
CAR T cell candidates with the goal of delivering readily available
cell therapy on-demand, more reliably, and at greater scale to more
patients. For more information, please visit www.allogene.com and
follow @AllogeneTx on Twitter and LinkedIn.
Cautionary Note on Forward-Looking
StatementsThis press release contains forward-looking
statements for purposes of the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995. The press release
may, in some cases, use terms such as "predicts," "believes,"
"potential," "proposed," "continue," "estimates," "anticipates,"
"expects," "plans," "intends," "may," "could," "might," "will,"
"should" or other words that convey uncertainty of future events or
outcomes to identify these forward-looking statements.
Forward-looking statements include statements regarding intentions,
beliefs, projections, outlook, analyses or current expectations
concerning, among other things: the ability to further research and
develop ALLO-213 or any other anti-DLL3 AlloCAR T candidate; and
the potential benefits of any anti-DLL3 AlloCAR T candidate or any
other AlloCAR T candidate. Various factors may cause differences
between Allogene’s expectations and actual results as discussed in
greater detail in Allogene’s filings with the SEC, including
without limitation in its Form 8-K filed on November 29, 2022 and
under the “Risk Factors” heading of its Form 10-Q for the quarter
ended September 30, 2022. Any forward-looking statements that are
made in this press release speak only as of the date of this press
release. Allogene assumes no obligation to update the
forward-looking statements whether as a result of new information,
future events or otherwise, after the date of this press
release.
AlloCAR T™ is a trademark of Allogene Therapeutics,
Inc.
Allogene’s AlloCAR T™ programs utilize Cellectis technologies.
The anti-DLL3 AlloCAR T programs are licensed exclusively from
Cellectis by Allogene and Allogene holds global development and
commercial rights to these AlloCAR T programs.
Allogene Media/Investor Contact:Christine
CassianoChief Communications Officer(714)
552-0326Christine.Cassiano@allogene.com
1Lung cancer - small cell - statistics. Cancer.Net. (2023,
January 6). Retrieved January 24, 2023, from
https://www.cancer.net/cancer-types/lung-cancer-small
cell/statistics#:~:text=Lung%20cancer%20is%20the%20second,be%20diagnosed%20with%20lung%20cancer
Allogene Therapeutics (NASDAQ:ALLO)
Historical Stock Chart
From Apr 2024 to May 2024
Allogene Therapeutics (NASDAQ:ALLO)
Historical Stock Chart
From May 2023 to May 2024